Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 27, Issue 3, 2013, Pages 373-384

  Nemeth, Edward F ^a   Shoback, Dolores ^b  

^a MetisMedica   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

calcilytic; calcimimetic; calcium sensing receptor; cinacalcet; hypercalcemia; hyperparathyroidism; hypophosphatemia; osteoporosis

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCILYTIC DRUG; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CINACALCET; DOXERCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D STEROL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG REPOSITIONING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL BENIGN HYPOCALCIURIC HYPERCALCEMIA; FAMILIAL DISEASE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); MULTIPLE ENDOCRINE NEOPLASIA; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEONATAL SEVERE PRIMARY HYPERPARATHYROIDISM; NEPHROLITHIASIS; NEWBORN DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PARATHYROID TUMOR; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL OSTEODYSTROPHY; SALURESIS; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VITAMIN BLOOD LEVEL; VOMITING;

CALCILYTIC; CALCIMIMETIC; CALCIUM-SENSING RECEPTOR; CINACALCET; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; OSTEOPOROSIS;

CALCIMIMETIC AGENTS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; HYPOPHOSPHATEMIA; OSTEOPOROSIS; RECEPTORS, CALCIUM-SENSING;

EID: 84880287294     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2013.02.008     Document Type: Conference Paper

References (35)

1. E.F. Nemeth Allosteric modulators of the extracellular calcium receptor Drug Discovery Today: Technologies 2013 10.1016/j.ddtec.2012.11.002
2. D.M. Shoback, J.P. Bilezikian, and S.A. Turner The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism Journal of Clinical Endocrinology and Metabolism 88 2003 5644 5649
3. M. Peacock, J.P. Bilezikian, and P.S. Klassen Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism Journal of Clinical Endocrinology and Metabolism 90 2005 135 141
4. M. Peacock, M.A. Bolognese, and M. Borofsky Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study Journal of Clinical Endocrinology and Metabolism 94 2009 4860 4867
5. C. Marcocci, P. Chanson, and D. Shoback Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism Journal of Clinical Endocrinology and Metabolism 94 2009 2766 2772
6. A. Falchetti, C. Cilotti, and L. Vagelli A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet Nature Clinical Practice: Endocrinology and Metabolism 4 2008 351 357
7. V.J. Moyes, J.P. Monson, and S.L. Ches Clinical use of cinacalcet in MEN1 hyperparathyroidism International Journal of Endocrinology 2010 2010 906163
8. M. Filopanti, U. Verga, and Ermetici MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly European Journal of Endocrinology 167 2012 157 164
9. C.M.S. Reh, G.N. Hendy, and D.E.C. Cole Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet Journal of Clinical Endocrinology and Metabolism 96 2011 E707 E712
10. A. Wilhelm-Bals, P. Parvex, and C. Magdelaine Successful use of bisphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism Pediatrics 129 2012 e812 e816
11. U.S. Alon, and VanDeVoorde Beneficial effect of cinacalcet in a child with familial hypocalciuric hypercalcemia Pediatric Nephrology 25 2010 1747 1750
12. S.J. Silverberg, M.R. Rubin, and C. Faiman Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma Journal of Clinical Endocrinology and Metabolism 92 2007 3803 3808
13. J.L. Geller, A. Khosravi, and M.H. Kelly Cinacalcet in the management of tumor-induced osteomalacia Journal of Bone and Mineral Research 22 2007 931 937
14. U.S. Alon, L. Levy-Olomucki, and W.V. Moore Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets Clinical Journal of the American Society of Nephrology 3 2008 658 664
15. E.F. Nemeth Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral bone disorder K. Olgaard, I.B. Salusky, J. Silver, The spectrum of mineral and bone disorders in chronic kidney disease 2nd ed. 2010 Oxford University Press Oxford p. 443-61
16. S.M. Moe, J. Cunningham, and J. Bommer Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl Nephrology Dialysis Transplantation 20 2005 2186 2193
17. S. Fishbane, W.B. Shapiro, and D.B. Corry Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results Clinical Journal of the American Society of Nephrology 3 2008 1718 1725
18. M. Ketteler, K.J. Martin, and M. Wolf Paracalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study Nephrology Dialysis Transplantation 27 2012 3270 3278
19. J.R. Stubbs, and J.B. Wetmore Does it matter how parathyroid hormone levels are suppressed in secondary hyperparathyroidism? Seminars in Dialysis 24 2011 298 306
20. G. Behets, G. Spasovski, and D.M. Spiegel Bone histomorphometry before and after 12 months of treatment with cinacalcet among dialysis patients with secondary hyperparathyroidism (HPT) ISN Nexus Symposium: Bone and Kidney. Book of Abstracts 2012 p.43
21. G.M. Chertow, Z.J. Lu, and X. Xu Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathryoidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols Hemodialysis International 16 2012 188 197
22. H. Komaba, S. Nakanishi, and A. Fujimori Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism Clinical Journal of the American Society of Nephrology 5 2012 2305 2314
23. M. Ichii, E. Ishimura, and S. Okuno Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism Nephron Clinical Practice 115 2010 c195 c202
24. T. Hirai, A. Nakashima, and N. Takasugi Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size Nephron Clinical Practice 114 2010 c187 c193
25. P. Raggi, G.M. Chertow, and P.U. Torres The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis Nephrology Dialysis Transplantation 26 2011 1327 1339
26. G.A. Block, D. Zaun, and G. Smits Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients Kidney International 78 2010 578 589
27. M. Evans, and C.M. Fored Lead-time bias in studies of cinacalcet presciptions Kidney International 78 2010 535 537
28. EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis New England Journal of Medicine 367 2012 2482 2494
29. J.B. Cohen, C.E. Gordon, and E.M. Balk Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis Transplantation 94 2012 1041 1048
30. D. Padhi, C.B. Langman, and S. Fathallah-Shaykh An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects Pediatric Nephrology 27 2012 1953 1959
31. M. Chonchol, F. Locatelli, and H.E. Abboud A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis American Journal of Kidney Diseases 2009 197 207
32. E.F. Nemeth Anabolic therapy for osteoporosis: calcilytics IBMS BoneKEy 5 2008 196 208
33. L.A. Fitzpatrick, C.E. Dabrowski, and G. Cicconetti Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women Journal of Bone and Mineral Research 27 2012 255 262
34. J. Halse, S. Greenspan, and F. Cosman A Phase IIb, randomized, placebo-controlled, dose-ranging study of MK-5442 in the treatment of postmenopausal women with osteoporosis 2012 American Society of Bone and Mineral Research Annual Meeting FR0361
35. 2+-sensing receptor regulates bone development, mineralization, and turnover Journal of Bone and Mineral Research 26 2011 2935 2947